Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127642341 | 12764234 | 1 | I | 2012 | 20160912 | 20160920 | 20160920 | PER | US-ASTRAZENECA-2016SE97929 | ASTRAZENECA | 40.00 | YR | F | Y | 49.00000 | KG | 20160920 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127642341 | 12764234 | 1 | PS | SEROQUEL XR | QUETIAPINE FUMARATE | 1 | Oral | QUETIAPINE150.0MG UNKNOWN | 0 | 150 | MG | FILM-COATED TABLET | |||||||
| 127642341 | 12764234 | 2 | SS | SEROQUEL XR | QUETIAPINE FUMARATE | 1 | Oral | QUETIAPINE150.0MG UNKNOWN | 0 | 150 | MG | FILM-COATED TABLET | |||||||
| 127642341 | 12764234 | 3 | SS | SEROQUEL XR | QUETIAPINE FUMARATE | 1 | Oral | 300.0MG UNKNOWN | 0 | 300 | MG | PROLONGED-RELEASE TABLET | QD | ||||||
| 127642341 | 12764234 | 4 | SS | SEROQUEL XR | QUETIAPINE FUMARATE | 1 | Oral | 300.0MG UNKNOWN | 0 | 300 | MG | PROLONGED-RELEASE TABLET | QD | ||||||
| 127642341 | 12764234 | 5 | SS | SEROQUEL XR | QUETIAPINE FUMARATE | 1 | Oral | QUETIAPINE150.0MG UNKNOWN | 0 | 150 | MG | FILM-COATED TABLET | |||||||
| 127642341 | 12764234 | 6 | SS | SEROQUEL XR | QUETIAPINE FUMARATE | 1 | Oral | QUETIAPINE150.0MG UNKNOWN | 0 | 150 | MG | FILM-COATED TABLET | |||||||
| 127642341 | 12764234 | 7 | C | GABAPENTIN. | GABAPENTIN | 1 | Oral | 0 | 1800 | MG | QD | ||||||||
| 127642341 | 12764234 | 8 | C | CITALOPRAM | CITALOPRAM HYDROBROMIDE | 1 | Oral | 0 | 40 | MG | QD | ||||||||
| 127642341 | 12764234 | 9 | C | TRAZODONE | TRAZODONE HYDROCHLORIDE | 1 | Oral | 0 | 100 | MG | QD | ||||||||
| 127642341 | 12764234 | 10 | C | CLONAZEPAM. | CLONAZEPAM | 1 | Oral | 1.0MG UNKNOWN | 0 | 1 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127642341 | 12764234 | 1 | Psychotic disorder |
| 127642341 | 12764234 | 2 | Major depression |
| 127642341 | 12764234 | 3 | Psychotic disorder |
| 127642341 | 12764234 | 4 | Major depression |
| 127642341 | 12764234 | 5 | Psychotic disorder |
| 127642341 | 12764234 | 6 | Major depression |
| 127642341 | 12764234 | 7 | Neuropathy peripheral |
| 127642341 | 12764234 | 8 | Major depression |
| 127642341 | 12764234 | 9 | Sleep disorder |
| 127642341 | 12764234 | 10 | Anxiety |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127642341 | 12764234 | HO |
| 127642341 | 12764234 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127642341 | 12764234 | Drug dose omission | |
| 127642341 | 12764234 | Hypothyroidism | |
| 127642341 | 12764234 | Intentional product misuse | |
| 127642341 | 12764234 | Memory impairment | |
| 127642341 | 12764234 | Off label use | |
| 127642341 | 12764234 | Product use issue | |
| 127642341 | 12764234 | Suicidal ideation |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127642341 | 12764234 | 1 | 2012 | 2016 | 0 | |
| 127642341 | 12764234 | 2 | 2012 | 2016 | 0 | |
| 127642341 | 12764234 | 3 | 20160830 | 20160911 | 0 | |
| 127642341 | 12764234 | 4 | 20160830 | 20160911 | 0 | |
| 127642341 | 12764234 | 5 | 20160912 | 0 | ||
| 127642341 | 12764234 | 6 | 20160912 | 0 | ||
| 127642341 | 12764234 | 7 | 2012 | 0 | ||
| 127642341 | 12764234 | 8 | 2013 | 0 | ||
| 127642341 | 12764234 | 9 | 2014 | 0 | ||
| 127642341 | 12764234 | 10 | 2013 | 0 |